Materials and Methods
Miconazole, imidazole 1-(2,4-dichloro-beta(2,4-dichloro-benziloxi) fenetil) nitrate was administered to 12 patients at the Evandro Chagas Hospital, Rio de Janeiro from July 1974 to November 1975. All were Brazilian and all came from a rural environment. There were 10 males and 2 females, 7 white and 5 mulatto. Ages ranged from 34 to 65 years old.
In 2 cases, the mycotic lesions were localized only in the cutaneous and mucosal regions, with slight lymphatic involvement. In the remaining 10 cases the infection was systemic, also showing pulmonary involvement. In all the cases the diagnosis was based on the presence of fungi, revealed by mycological and or histopathological examination.
Ten patients were being treated for the first time, specifically for this kind of mycosis. One of the remaining 2 had previously been treated with sulphonamide compounds and amphotericin B and the other had been submitted to an unsatisfactory course of sulphonamide therapy.
Miconazole tablets (500 mg) were administered at a daily dose of 3 g (1 g three times daily) by the oral route, except for one patient who had previously received a different specific therapy. During the first month of treatment, this patient received intravenous miconazole (200 mg diluted in 250 ml of 5 % glucose solution) plus 1 g twice daily by mouth. The Healing of oral lesions after one month of treatment with miconazole. At the end of 4 months of treatment, lymphatics were still palpable. Treatment was interrupted at the end of the fourth month. The patient did not return to follow up. Diarrhoeea was observed during the treatment, but was controlled with temporary use of intestinal adsorbents. In April 1974, miconazole administration was begun. During the initial 4 weeks of treatment this patient had his first daily dose replaced by an intravenous application of 200 mg of miconazole diluted in 250 ml of glucose solution, together with two oral doses of 1 g. At the beginning of the new therapy, the patient presented cutaneomucous (labial fissure) and pulmonary lesions. The latter regressed in 4 months. The cutaneomucous lesions were eradicated in 15 days. period of treatment: 6 months. No side-effects were reported. Follow up: Four months after finishing treatment there was no clinical relapse.
Results
The period of treatment ranged from three to eight months. In all patients the administration of miconazole led to a complete regression of cutaneous and oral, nasal, pharyngeal and laryngeal mucosal lesions in 8 periods ranging from two to six weeks. Although the patients showed a quick therapeutic response, it was established that maintenance of treatment should continue for not less than four months.
The pulmonary and lymphatic lesions receded more slowly. Six months of treatment was necessary in one case for clinical and radiological evidence of complete pulmonary cure. For this type of patient the need for medication for two months after complete involution of the lesions was established by clinical and radiologic evaluation. In 2 patients the lymphatics remained palpable at the end of treatment.
Side-effects were observed in 6 patients, all related with the digestive tract. There was one case of nausea and vomiting and 5 cases of diarrhcea. These reactions were easily controlled by the use of an antiemetic/antacid and an intestinal adsorbent. In only one patient did diarrheea lead to the interruption of drug administration at the end of the third month, at The duration of follow up in this series ranged (up to the time when these data were computedJanuary 1976) from three to 15 months, in 9 patients. The remaining three patients did not return for post-therapeutic evaluation and one of them dropped out before completing the time scheduled for medication. This follow-up study should continue for a period of five years.
The individual data relating to the period of treatment, results and follow up are reported in Table 1 .
Discussion
This extension of a previous report shows, in a greater number of patients and with a more extensive post-therapeutic follow up, that miconazole, administered solely by the oral route, is a potent and effective chemotherapeutic agent in the cure of the lesions observed in paracoccidioidomycosis. However, from experience obtained with the sulphonamides and amphotericin B, the cure can only be considered as definitive after a five-year period of follow up without drug administration.
In these extended clinical observations, the rapid regression of the acute lesions was confirmed, as well as the maintenance of the clinical cure in all the cases studied, although the followup period is still quite short.
Seemingly, miconazole presents advantages over the therapeutic agents now utilized in the treatment of South-American blastomycosis. Case 12 of this series shows such an apparent superiority. This patient presented relapses in a short time (three to four weeks) after completing treatments with either sulphonamides or with amphotericin B; after miconazole administration his lesions have been healed for four months.
With regard to tolerance, diarrhoea was the only frequent side-effect. However, it did not usually cause discontinuation of the treatment since it was easily and quickly controlled through specific medication (kaolin, pectin, &c.).
An exception was Case 4, where this side-effect was not controlled, causing the interruption of the planned therapeutic scheme. In this patient, who had oral, pulmonary and lymphatic lesions, it was possible to continue medication for only three months, but nonetheless post-therapeutic follow up at 14 months gave proof of clinical cure.
It is of considerable importance to investigate the possible causes of this delayed diarrheea, which might be due to a local irritation or to a change in the balance of the intestinal flora caused by the antimicrobial action of the drug.
With regard to toxicity the usual methods of investigation failed to reveal any significant druginduced alterations in any of the parameters examined.
In conclusion, these extended observations confirm our initial conclusions as to the effectiveness of miconazole given by the oral route, in the treatment of paracoccidioidomycosis.
Summary
Results are presented from 12 patients of both sexes, whose ages range from 34 to 65 years, observed over a period of 16 months and receiving miconazole treatment for SouthAmerican blastomycosis. Ten of them were being treated for the first time and the remaining 2 presented relapses after treatment with other chemotherapeutic agents.
The blastomycotic lesions were localized in skin, mucosa, lung and lymphatics. The drug was administered orally, at a dosage of 1 g three times daily. One relapsing patient had his first daily oral dose replaced by an intravenous dose of 200 mg of miconazole diluted in 250 ml of glucose solution during the initial four weeks.
The criterion for diagnosis was finding of the fungus in sputum and/or in the material collected through scrapings or biopsy of the lesions. All patients were treated in hospital until the cure was apparent, clinical examinations being conducted weekly and bi-weekly.
Bi-weekly laboratory examinations were performed to evaluate the patient's tolerance to the drug. Dr Macedo (Brazil) said that they had found no reason for the late diarrhoea, but thought it could have been caused by the use of 500 mg tablets of miconazole nitrate in the study. In 4 of the 5 cases the late diarrhoea had been well controlled with adsorbents, so it had not caused alarm. The only patient with delayed diarrhoea in whom they had to interrupt administration of the drug because of this side-effect had fortunately already been cured of the mucosal and pulmonary lesions.
Dr D Deppermann (Heidelberg) asked if the patients had had a bloody diarrheea.
Dr Macedo replied that they had not.
Dr R Negroni (Buenos Aires) felt that diarrhoea was a question of miconazole dosage. He had observed that in some patients the diarrheea ceased when the oral dose was reduced. He thought the tablets used by Dr Lima and colleagues had caused the diarrhoea. It was double the dose used in Argentina.
